Abstracts tagged "Lupus"

Abstract Number: 1352 • 2018 ACR/ARHP Annual Meeting
Low Density Granulocytes in Idiopathic Inflammatory Myopathy
David Fernandez¹, Linjia Jia², Mikhail Olferiev³, Annel M. Fernandez⁴, JoAnn Vega⁵, Kerri Merritt⁶, Michael Lockshin⁷ and Peggy Crow¹, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ³Mary Kirkland Center for Lupus Research, Hospital for Special Surgery, New York, NY, ⁴Medicine- Rheumatology/ Research, Hospital for Special Surgery, New York, NY, ⁵Medicine - Rheumatology / Research, Hospital for Special Surgery, New York, NY, ⁶Hospital for Special Surgery, New York, NY, ⁷Barbara Volcker Center, Hospital for Special Surgery, New York, NY
Background/Purpose: Idiopathic Inflammatory Myopathy (IIM) is a group of autoimmune diseases characterized by immune-mediated injury to skeletal muscle, including polymyositis (PM) and dermatomyositis (DM). Recent…
Abstract Number: 2030 • 2018 ACR/ARHP Annual Meeting
Patients with Childhood-Onset SLE (cSLE) and Hypertension Have Consistently Higher Serum Concentrations of C3 and C4 Than Those without Hypertension
Evan Mulvihill¹, Stacy P. Ardoin², Susan D Thompson³, Bi Zhou⁴, Gakit Yu⁵, Nora G. Singer⁶, Deborah M. Levy⁷, Hermine I. Brunner⁸, Yee Ling Wu⁹, Haikady Nagaraja¹⁰, Laura E. Schanberg¹¹ and Chack-Yung Yu², ¹Pediatrics and Rheumatology, Nationwide Children's Hospital, Columbus, OH, ²Division of Rheumatology, Nationwide Children’s Hospital, Columbus, OH, ³Center for Autoimmune Genomics and Etiology (CAGE), Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Center for Molecular and Human Genetics, The Research Institute at Nationwide Children's Hospital and The Ohio State University, Columbus, OH, ⁵Center for Molecular and Human Genetics, Nationwide Children's Hospital, Columbus, OH, ⁶Departments of Medicine and Pediatrics, Division of Rheumatology, MetroHealth Medical Center, Cleveland, OH, Cleveland, OH, ⁷Rheumatology, Hospital for Sick Children, Toronto, ON, Canada, ⁸Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ⁹Department of Microbiology and Immunology, Loyola University Chicago, Chicago, IL, ¹⁰College of Public Health, The Ohio State University, Columbus, OH, ¹¹Duke University Medical Center, Durham, NC
Background/Purpose: Chronic systemic inflammation, mediated in part by complement, and inadequate vascular repair mechanisms affect patients with cSLE from a young age and are associated…
Abstract Number: 2657 • 2018 ACR/ARHP Annual Meeting
Assessment of Habitual Physical Activity and Performance during Maximal Exercise Test in Systemic Lupus Erythematosus Patients
Rosane Machado¹, Nilzio A. da Silva^1,2, Vitalina Barbosa¹, Jozelia Rêgo¹, Heloísa Machado¹, Claúdio Lira¹ and Ricardo Viana¹, ¹Universidade Federal de Goiás, Goiânia, Brazil, ²GLADEL, Goias, Brazil
Background/Purpose: Patients with systemic lupus erythematosus (SLE) present low physical capacity when compared to healthy controls. In addition to chronotropic incompetence during exercise, slow recovery…
Abstract Number: 193 • 2018 ACR/ARHP Annual Meeting
Practice Improvement Using Virtual Online Training: A Novel App-Based Platform to Teach Clinical Reasoning in Rheumatology
Megan Lockwood¹, Jennifer Mandal², Sebastian Andreatta³ and Maria Dall'Era³, ¹Internal Medicine, University of California, San Francisco, San Francisco, CA, ²Rheumatology, University of California, San Francisco, San Francisco, CA, ³University of California, San Francisco, San Francisco, CA
Background/Purpose: The demand for rheumatologists continues to increase due to the high prevalence of rheumatic disease in a growing population. As outlined in ACR's 2015…
Abstract Number: 722 • 2018 ACR/ARHP Annual Meeting
Increased Blood Pressure Visit-to-Visit Variability in Patients with Systemic Lupus Erythematosus: Association with Inflammation, Comorbidities and Increased Mortality
Tyler Reese¹, Alyson Dickson¹, Jacquelyn E. Neal², Jocelyn S. Gandelman³, Omair A. Khan², April Barnado⁴, William Dupont², C. Michael Stein¹ and Cecilia P. Chung¹, ¹Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, ²Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, ³Vanderbilt University School of Medicine, Nashville, TN, ⁴Division of Rheumatology and Immunology, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Patients with systemic lupus erythematosus (SLE) have increased mortality compared to the general population. As outcomes related to disease control have improved, this mortality…
Abstract Number: 1405 • 2018 ACR/ARHP Annual Meeting
Assessment of the Psychometric Properties of Patient-Reported Outcomes of Depression in SLE
Andrew Kwan¹, Sherief Marzouk², Helia Ghanean², Michelle Vitti³, Kishwar Ali³, Dennisse Bonilla³, Nicole Anderson³, Jiandong Su³ and Zahi Touma³, ¹Faculty of Medicine, Queen's University, Kingston, ON, Canada, ²Psychiatry, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Mood disorders, including depression, are amongst the most common manifestations of neuro-psychiatric SLE. Currently, the screening and diagnosis for depression in ambulatory settings are…
Abstract Number: 2087 • 2018 ACR/ARHP Annual Meeting
Kidney Tissue Damage in Mice with Single and Combined Abnormalities in Complement, Interferon and Apoptotic Cell Clearance
Sladjana Skopelja-Gardner¹, YuFeng Peng², Payton Hermanson², Lucrezia Colonna², Xizhang Sun³, Lena Tanaka⁴, Anne Davidson⁵, David Salant⁶ and Keith B. Elkon⁷, ¹Division of Rheumatology, Department of Medicine, University of Washington, Seattle, WA, ²Division of Rheumatology, University of Washington, Seattle, WA, ³Rheumatology, University of Washington, Seattle, WA, ⁴Medicine/Rheumatology, University of Washington, Seattle, WA, ⁵Autoimmunity and Musculoskeletal Diseases, Feinstein Institute for Medical Research, Manhasset, NY, ⁶Boston University, Boston, MA, ⁷University of Washington, Seattle, WA
Background/Purpose: Lupus nephritis (LN) affects ~70% of systemic lupus erythematosus (SLE) patients and is one of the main contributors to morbidity and mortality. While defective…
Abstract Number: 2666 • 2018 ACR/ARHP Annual Meeting
Trends in Treatment of Systemic Lupus Erythematosus and Lupus Nephritis: 2006-2016
Ali Duarte-Garcia¹, Cynthia S. Crowson², Rozalina McCoy¹, Stephanie Schilz³, Holly Van Houten⁴, Lindsey Sangaralingham⁴, Vaidehi R. Chowdhary⁵, Shreyasee Amin⁶, Kenneth J. Warrington⁷, Eric L. Matteson⁸ and Nilay Shah⁹, ¹Mayo Clinic College of Medicine and Science, Rochester, MN, ²Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, ³Health Sciences Research, Mayo Clinic, Rochester, MN, ⁴Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN, ⁵Internal Medicine, Division of Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN, ⁶Rheumatology, Mayo Clinic, Rochester, MN, ⁷Rheumatology, Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, MN, ⁸Division of Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN, ⁹Health Care Policy and Research, Mayo Clinic College of Medicine and Science, Rochester, MN
Background/Purpose: Glucocorticoids, anti-malarials and conventional immunosuppressive agents have been the mainstay of therapy for systemic lupus erythematosus (SLE) and lupus nephritis (LN); more recently biologic…
Abstract Number: 228 • 2018 ACR/ARHP Annual Meeting
Widespread Chronic Use of Proton-Pump Inhibitors and Potential for Drug-Drug Interactions in Rheumatoid Arthritis and Lupus Patients
Daniel Keebler¹, Nicholas Jones¹ and Matthew McEnany², ¹Genentech, Inc., South San Francisco, CA, ²Genesis Research, Hoboken, NJ
Background/Purpose: Poor control of rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) can lead to the use of corticosteroids and non-steroidal anti-inflammatories (NSAIDs), which in…
Abstract Number: 724 • 2018 ACR/ARHP Annual Meeting
Are Traditional Biomarkers of Lupus Associated with Renal Pathology in Lupus Nephritis?
Kelly Liang¹, Kimberly P. Liang², Yaming Li³, Alex Hurd³, Douglas Landsittel⁴ and Sheldon Bastacky⁵, ¹Medicine, Renal-Electrolyte Division, University of Pittsburgh, Pittsburgh, PA, ²Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ³Biostatistics, University of Pittsburgh, Pittsburgh, PA, ⁴Biomedical Informatics, University of Pittsburgh, Pittsburgh, PA, ⁵Pathology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Traditional biomarkers for systemic lupus erythematosus (SLE) and lupus nephritis (LN) include serum creatinine (Cr), complement levels (C3/C4), double-stranded DNA antibody (dsDNA), erythrocyte sedimentation…
Abstract Number: 1666 • 2018 ACR/ARHP Annual Meeting
The Use of Patient-Reported Outcome Measures to Assess Clinical Features of Fibromyalgia in SLE
Jennifer Rogers¹, Amanda M. Eudy², Lisa Criscione-Schreiber², David Pisetsky³, Kai Sun⁴, Jay Doss⁴ and Megan E. B. Clowse², ¹Medicine, Divison of Rheumatology, Duke University, Durham, NC, ²Department of Medicine, Division of Rheumatology and Immunology, Duke University, Durham, NC, ³Department of Medicine, Duke University, Durham, NC, ⁴Division of Rheumatology & Immunology, Duke University, Durham, NC
Background/Purpose: Patient-reported outcome measures (PROs) in SLE can capture patient specific information and the patient perspective, but clinical use can be challenging due to confounding…
Abstract Number: 2089 • 2018 ACR/ARHP Annual Meeting
The Differential Impact of the Abrogation of the Costimulatory Molecule CD137 Ligand on Renal and Cerebral Manifestations in C57BL/6.Faslpr-/- mice
Anselm Mak¹, Bhushan Dharmadhikari², Lik Wei Wong², Saji Kumar Sreedharan² and Herbert Schwarz², ¹Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore, ²Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
Background/Purpose: Costimulatory molecules which mediate cross-talks between leukocytes, have been identified to play a pathogenetic pivotal role in systemic lupus erythematosus (SLE). Abrogation of the…
Abstract Number: 2675 • 2018 ACR/ARHP Annual Meeting
Age-Related Metabolic Changes Underlie Pro-Inflammatory Lineage Specification and Contribute to Therapeutic Responsiveness to Mechanistic Target of Rapamycin Blockade in SLE
Zhi-Wei Lai¹, Ryan Kelly² and Andras Perl¹, ¹Medicine, SUNY Upstate Medical University, Syracuse, NY, ²SUNY, Syracuse, NY
Background/Purpose: Systemic lupus erythematosus (SLE) patients exhibit T-cell dysfunction which can be reversed by blockade of the mechanistic target of rapamycin (mTOR) with therapeutic efficacy…
Abstract Number: 267 • 2018 ACR/ARHP Annual Meeting
Patterns of Access to Prescription Medications Among Lupus Cases and Controls in the Population-Based Michigan Lupus Epidemiology & Surveillance (MILES) Cohort
Deeba Minhas¹, Wendy Marder¹, Siobán Harlow², Suzanna Zick³, Afton L. Hassett⁴, Kamil E. Barbour⁵, Charles G. Helmick⁵, Caroline Gordon⁶, Jiha Lee¹, Amrita Padda¹, W. Joseph McCune¹ and Emily C. Somers¹, ¹Rheumatology, University of Michigan, Ann Arbor, MI, ²Epidemiology Department- School of Public Health, Obstetrics and Gynecology- Medical School, University of Michigan, Ann Arbor, MI, ³Department of Family Medicine, University of Michigan, Ann Arbor, MI, ⁴Anesthesiology, University of Michigan, Ann Arbor, MI, ⁵Arthritis Program, Centers for Disease Control and Prevention, Atlanta, GA, ⁶University of Birmingham, Birmingham, United Kingdom
Background/Purpose: Medication access and adherence are important issues in determining patient outcomes. We investigated sociodemographic factors and disparities associated with prescription medication access in a…
Abstract Number: 727 • 2018 ACR/ARHP Annual Meeting
Increased Risk of Coronary Artery Disease Among Patients with Class III Lupus Nephritis: A Retrospective Study of Patients at the University of North Carolina at Chapel Hill
Enid Y Sun¹, Carolina Alvarez² and Saira Z Sheikh³, ¹Internal Medicine, University of North Carolina, Chapel Hill, NC, ²Thurston Arthritis Research Center, Department of Medicine, University of North Carolina, Chapel Hill, NC, ³University of North Carolina at Chapel Hill, Chapel Hill, NC
Background/Purpose: Patients with systemic lupus erythematosus (SLE) are at an increased risk for developing coronary artery disease (CAD) compared to their cohorts without lupus. There…

« Previous Page
1
…
7
8
9
10
11
…
31
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at abstracts@rheumatology.org.